Quick Answer
REGENXBIO Inc. reported Research And Development Expense of $228.30 million for the year ending 2025.
- REGENXBIO Inc. showed an increase of +9.5% in Research And Development Expense from 2024 to 2025.
- This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $1.09 million | Q1 2015: $2.79 million | Q2 2015: $4.01 million | Q3 2015: $5.66 million | Q4 2015: $4.81 million | Q1 2016: $6.18 million | Q2 2016: $10.68 million | Q3 2016: $12.56 million | Q4 2016: $16.06 million | Q1 2017: $16.62 million | Q2 2017: $13.92 million | Q3 2017: $12.52 million | Q4 2017: $14.17 million | Q1 2018: $19.55 million | Q2 2018: $21.49 million | Q3 2018: $18.51 million | Q4 2018: $24.33 million | Q1 2019: $25.20 million | Q2 2019: $29.48 million | Q3 2019: $35.69 million | Q4 2019: $33.81 million | Q1 2020: $37.04 million | Q2 2020: $38.11 million | Q3 2020: $43.97 million | Q4 2020: $47.18 million | Q1 2021: $39.72 million | Q2 2021: $45.88 million | Q3 2021: $47.86 million | Q1 2022: $55.63 million | Q2 2022: $61.01 million | Q3 2022: $63.31 million | Q1 2023: $58.52 million | Q2 2023: $59.89 million | Q3 2023: $58.18 million | Q1 2024: $54.84 million | Q2 2024: $48.87 million | Q3 2024: $54.43 million | Q1 2025: $53.09 million | Q2 2025: $59.50 million | Q3 2025: $56.10 million.
- Over the full 13 years of available data (2013 to 2025), REGENXBIO Inc.'s Research And Development Expense has grown by 4,419.9%.
- Historical annual values: Fiscal year 2025: $228.30 million | Fiscal year 2024: $208.52 million | Fiscal year 2023: $232.27 million | Fiscal year 2022: $242.45 million | Fiscal year 2021: $181.44 million | Fiscal year 2020: $166.29 million | Fiscal year 2019: $124.19 million | Fiscal year 2018: $83.87 million | Fiscal year 2017: $57.22 million | Fiscal year 2016: $45.48 million | Fiscal year 2015: $17.28 million | Fiscal year 2014: $4.96 million | Fiscal year 2013: $5.05 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: